SiPhox Health, a Burlington, MA-based company which specializes in building a lab-grade home health testing with silicon photonics, raised $27M in Seed and Series A funding.
The Series A round was led by Intel Capital with participation from Khosla Ventures, Kortex Ventures, Alumni Ventures, Metaplanet, Shorewind Capital, LongeVC, Overlap Holdings and Duke Capital Partners.
The Seed funding was led by Khosla Ventures and Y Combinator with participation from Metaplanet, Massachusetts Manufacturing Innovation Initiative, Rsquared, Vituity, Paul Buchheit, Balaji Srinivasan, Bob Lee, and Longevity Tech Fund among others.
Intel Capital managing director Srini Ananth will also join SiPhox Health’s board of directors.
Led by CEO Diedrik Vermeulen and CPO Michael Dubrovsky, SiPhox Health specializes in optical biochip technology and is introducing integrated photonics into home healthcare. Its Home and Health testing systems offer blood collection solutions for consumers, healthcare systems, pharmaceutical companies, and research teams focusing on longevity and chronic disease management.
The Series A funding will enable team expansion as SiPhox Health works towards FDA clearance for its SiPhox Home platform, which will offer a broad menu of proteins and hormone tests from a finger prick blood sample, with results in five minutes or less. In the meantime, SiPhox Health has launched a mail-in blood collection kit that measures 17 biomarkers for inflammation, metabolic, hormonal and cardiovascular health.
The SiPhox Home, currently available for investigational use only, features a growing menu of multiplexed protein and hormone tests designed for home use.
FinSMEs
19/07/2023